We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

XCH:NASDAQXCHG Limited Analysis

Data as of 2026-06-10 - not real-time

$0.64

Latest Price

8/10Risk

Risk Level: High

Executive Summary

XCHG Limited is trading at $0.64, which sits below its 20‑day (≈$0.69), 50‑day (≈$0.91) and 200‑day (≈$1.17) simple moving averages, signaling a bearish price environment. The RSI of 40.7 suggests the stock is not yet oversold, while the MACD line has just crossed above its signal, producing a modest positive histogram that hints at a fleeting bullish impulse but does not outweigh the prevailing downtrend. Volume is increasing yet remains thin relative to the company’s market cap, and a beta of 2.25 combined with a 30‑day volatility of over 130% underscores a highly volatile, high‑beta profile. Fundamentally, the firm reports negative margins across the board, a trailing EPS of –$0.40, and a DCF‑derived fair value of roughly $0.26, implying the current price is overvalued. The recent appointment of Albina Iljasov as co‑CEO introduces a potential strategic pivot, but the impact on earnings remains uncertain. Overall, the technical and fundamental signals point to continued pressure on the share price, with limited upside unless the new leadership can quickly reverse the loss trajectory.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below all major SMAs
  • High beta and extreme short‑term volatility
  • Negative earnings and widening loss margins

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential strategic shift from new co‑CEO
  • Improving volume trend indicating some investor interest
  • Continued cash balance versus modest debt

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Sustained negative profitability and cash‑flow pressure
  • DCF fair value far below current market price
  • Sector exposure to cyclical industrial machinery demand

Key Metrics & Analysis

Financial Health

Revenue Growth-42.60%
Profit Margin-129.49%
P/E Ratio-21.3
ROE-137.21%
ROA-40.85%
Debt/Equity45.73
P/B Ratio1.5
Op. Cash Flow$-7526683
Free Cash Flow$1.4M
Industry P/E30.5

Technical Analysis

TrendBearish
RSI40.7
Support$0.56
Resistance$0.96
MA 20$0.69
MA 50$0.91
MA 200$1.17
MACDBullish
VolumeIncreasing
Fear & Greed Index83.8

Valuation

Fair Value$0.26
GradeOvervalued
TypeValue

Risk Assessment

Beta2.25
Volatility132.13%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.